Oleg Tsodikov

Title: Oleg Tsodikov: Innovator in Cancer Treatment

Introduction

Oleg Tsodikov is a prominent inventor based in Lexington, KY (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of Mithramycin derivatives. With a total of 5 patents to his name, Tsodikov's work focuses on enhancing the selectivity and anti-cancer activity of these compounds.

Latest Patents

Tsodikov's latest patents include the development of Mithramycin (MTM) short side chain ketone (SK) derivatives and MTM short side chain diketone (SDK) derivatives. These derivatives are designed to treat cancer or neuro-diseases associated with an aberrant erythroblast transformation-specific transcription factor. Notably, the unique MTM SK and MTM SDK derivatives exhibit increased selectivity toward the ETS transcription factor. Additionally, he has developed Mithramycin side chain carboxylic acid (MTM-SA) derivatives, which encompass substituted amino acid derivatives, substituted amino acid dipeptide derivatives, or unsubstituted dipeptide derivatives. The MTM-SA derivatives also show promise in treating cancer or neuro-diseases linked to the same transcription factor, with enhanced selectivity toward the ETS transcription factor.

Career Highlights

Oleg Tsodikov is affiliated with the University of Kentucky Research Foundation, where he conducts his research. His work has garnered attention for its potential impact on cancer therapies and neuro-disease treatments.

Collaborations

Some of Tsodikov's notable coworkers include Jurgen Rohr and Markos Leggas, who contribute to the collaborative efforts in advancing research in this critical area.

Conclusion

Oleg Tsodikov's innovative work in developing Mithramycin derivatives represents a significant advancement in cancer treatment. His contributions continue to pave the way for new therapeutic options in the fight against cancer and neuro-diseases.